Abstract PS5-31: Molecular markers of response to s-equol, a novel oral estrogen receptor (ER) beta agonist for triple negative breast cancer
Kate Lathrop(The University of Texas MD Anderson Cancer Center), Richard Elledge(The University of Texas at San Antonio Health Science Center), Jonathan Gelfond(The University of Texas at San Antonio Health Science Center), Virginia Kaklamani(Northwestern University), Courtney Thomas(The University of Texas at San Antonio Health Science Center), Marisa Rodriguez(The University of Texas at San Antonio Health Science Center), Andrew Brenner(The University of Texas at San Antonio Health Science Center), Rong Li(University of Virginia), Alia Nazarullah(The University of Texas at San Antonio), Sarah Hackman(The University of Texas Health Science Center at Houston)
Cited by 2
Related Papers
Genetic/Familial High-Risk Assessment: Breast and Ovarian
|Journal of the National Comprehensive Cancer Network|2010|650
First results on survival from a large Phase 3 clinical trial of an autologous dendritic cell vaccine in newly diagnosed glioblastoma
|Journal of Translational Medicine|2018|540
Association of Autologous Tumor Lysate-Loaded Dendritic Cell Vaccination With Extension of Survival Among Patients With Newly Diagnosed and Recurrent Glioblastoma
|JAMA Oncology|2022|411
Imaging of Lymph Flow in Breast Cancer Patients after Microdose Administration of a Near-Infrared Fluorophore: Feasibility Study
|Radiology|2008|298
Synchronicity of frequently sampled, 24-h concentrations of circulating leptin, luteinizing hormone, and estradiol in healthy women
|Proceedings of the National Academy of Sciences|1998|294